SPAC23A1.14c Antibody

Absence in Published Literature

• The term "SPAC23A1.14c" does not appear in:

  • PubMed (including ),

  • ClinicalTrials.gov (e.g., ),

  • Antibody-specific repositories (e.g., Sino Biological , Microbe Notes ).

• No matches were found for this identifier in genomic, proteomic, or immunology databases (e.g., UniProt, GenBank, IMGT).

Nomenclature or Typographical Errors

• The alphanumeric format "SPAC23A1.14c" suggests a gene or protein identifier, but:

  • SPAC23A1 corresponds to a Schizosaccharomyces pombe (fission yeast) gene encoding a hypothetical protein.

  • The ".14c" suffix is inconsistent with standard antibody naming conventions (e.g., INN, WHO guidelines).

Proprietary or Undisclosed Research

• The compound may be:

  • In early preclinical development without public disclosure,

  • Part of confidential industry research (e.g., AbbVie trials focus on small molecules, not antibodies).

Recommendations for Further Inquiry

Related Antibody Research Context

While "SPAC23A1.14c" remains unverified, advancements in antibody engineering (e.g., HIV bNAbs in ) highlight methodologies that could apply to novel targets: